Skip to main content
SpringerLink
Log in

Thrombophile Zustände in der Intensivmedizin

Thrombophilic states in intensive care medicine

  • Leitthema
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

Zusammenfassung

Die thrombophilen Zustände gehören zum Alltag der Intensivmedizin. In der Regel sind sie Komplikationen lebensbedrohender Grunderkrankungen oder therapeutischer Maßnahmen. Sie besitzen eine hohe attributive Sterblichkeit. Frühe Erkennung und unverzügliche sowie konsequente Therapie sind deshalb unabdingbar.

Die vorliegende Übersicht stellt die wichtigen klinischen Aspekte von Diagnostik und Therapie zusammen, ohne die umfangreiche Literatur zu den Teilthemen in der Gesamtheit würdigen zu können. Leitsymptome und der Kontext zu den Grunderkrankungen sowie zu den Therapien, die thrombophile Zustände verursachen können, stellen die Weichen für die Labordiagnostik. Der höchste Evidenzgrad für nahezu alle therapeutischen Empfehlungen besteht derzeit in Expertenmeinungen.

Abstract

Thrombophilic states are common in intensive care medicine. Generally, they are complications of serious underlying diseases or adverse effects of treatment measures. The attributive mortality rate for thrombophilic states is high. Early recognition and management are, thus, indispensable. In this review, important diagnostic and therapeutic aspects are briefly summarized. Leading symptoms and the context to the underlying disease or therapy, which result in a thrombophilic state, are the basics for a specific diagnostic workup. Almost all current treatment recommendations are based on expert opinion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abraham E, Reinhart K, Opal S, Demeyer I et al (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. JAMA 290:238–247

    Article  PubMed  CAS  Google Scholar 

  2. Ariceta G, Besbas N, Johnson S, Karpman D et al (2009) Guideline for the investigation and initial therapy of diarrhea-negative haemolytic uremic syndrome. Pediatr Nephrol 24:687–696

    Article  PubMed  Google Scholar 

  3. AWMF-Leitlinien, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) (2008) Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. AWMF-Leitlinien-Register Nr.015/018. http://www.awmf.org/leitlinien/detail/ll/015-018.html. Zugegriffen am

  4. Bartz C, Rath W (2007) Aktuelles Management beim HELLP-Syndrom. Gynakol Geburtshilfliche Rundsch 47:215–221

    Article  PubMed  CAS  Google Scholar 

  5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709

    Article  PubMed  CAS  Google Scholar 

  6. British Society for Haemotology (2003) Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120:556–573

    Article  Google Scholar 

  7. Carlson LE, Lubenow N, Blumentritt C, Kempf R et al (2003) Platelet receptor and clotting factor polymorphism as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia (HIT). Pharmacogenetics 13:253–258

    Article  Google Scholar 

  8. Carreras E, Bertz H, Arcese W, Vernant JP et al (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 15:3599–3604

    Google Scholar 

  9. Davis AK, Makar RS, Stowell CP et al (2009) ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS 13. Transfusion 49:206–213

    Article  PubMed  CAS  Google Scholar 

  10. Dignan F, Gujral D, Ethell M et al (2007) Prophylactic defibrotide in allogenic stem cell transplantation: minimal morbitidy and zero mortality from veno-occlusive disease. Bone Marrow Transplant 40:79–82

    Article  PubMed  CAS  Google Scholar 

  11. Farner B, Eichler B, Kroll H, Greinacher A (2001) A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85:950–957

    PubMed  CAS  Google Scholar 

  12. Fonseca JE, Mendez F, Catano C, Arias F (2005) Dexamethasone treatment does not improve the outcome of women with HELLP-Syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 193:1591–1598

    Article  PubMed  CAS  Google Scholar 

  13. Furlan M, Robles R, Galbusera M, Remuzzi G et al (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584

    Article  PubMed  CAS  Google Scholar 

  14. George JN, Woodson RD, Kiss JE et al (2006) Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with systemic review of rituximab therapy for immune-mediated disorders. J Clin Apher 21:49–56

    Article  PubMed  Google Scholar 

  15. Greinacher A, Lubenow N, Hinz P, Ekkernkamp A (2003) Heparininduzierte Thrombozytopenie. Dtsch Arztebl 100:A2220–A2229

    Google Scholar 

  16. Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical haemolytic-uremic syndrome. N Engl J Med 360:544–546

    Article  PubMed  CAS  Google Scholar 

  17. Jasti S, Coyle T, Gentile T et al (2008) Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 23:151–156

    Article  PubMed  Google Scholar 

  18. Joshi D, James A, Quaglia A et al (2010) Liver disease in pregnancy. Lancet 375:594–605

    Article  PubMed  Google Scholar 

  19. Katz L, Amorim MMR de, Figueiroa JN, e Silva JLP (2008) Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 198:283.e1–283.e8

    Article  PubMed  Google Scholar 

  20. Klockenbusch W, Schrepfer F (2007) Aktuelle Empfehlungen bei Präeklampsie. Gynakol Geburtshilfliche Rundsch 47:209–214

    Article  PubMed  CAS  Google Scholar 

  21. Kirchmaier CM (1995) Ätiologie und Pathogenese der disseminierten intravasalen Gerinnung. Hamostaseologie 15:69–78

    CAS  Google Scholar 

  22. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T et al (2011) Eculizumab in severe shiga-toxin-associated HUS. N Engl J Med 364:2561–2563

    Article  PubMed  CAS  Google Scholar 

  23. McDonald GB, Sharma P, Matthews DE et al (1984) Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4:116–122

    Article  PubMed  CAS  Google Scholar 

  24. Menhorn VZ, Siegmund-Schultze K, Hibbeler B (2011) EHEC-Infektion. Nachsorge und Nachlese. Dtsch Arztebl 108:B1383–B1384

    Google Scholar 

  25. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600

    Article  PubMed  CAS  Google Scholar 

  26. Murrin R, Murray J (2006) Thrombotic thrombocytopenic purpura. Aetiology, pathophysiology and treatment. Blood Rev 20:51–60

    Article  PubMed  CAS  Google Scholar 

  27. Neuhaus T, Bayraktar DU (2010) Veno-occlusive disease (VOD). In: Pötzsch B, Madlener K (Hrsg) Hämostaseologie: Grundlagen, Diagnostik und Therapie, 2. Aufl. Springer, Berlin, S 563–568

  28. Noris M, Remuzzi G (2009) Atypical haemolytic-uremic syndrome. N Engl J Med 361:1676–1687

    Article  PubMed  CAS  Google Scholar 

  29. Nürnberger J, Philipp T, Witzke O, Saez AO et al (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542–544

    Article  PubMed  Google Scholar 

  30. Ochs A (2011) Akute Gefäßkomplikationen der Leber. Internist 52:795–803

    Article  PubMed  CAS  Google Scholar 

  31. Piercefield EW, Bradley KK, Coffman RL, Mallonee SW (2010) Hemolytic uremic syndrome after an Escherichia coli O111 outbreak. Arch Intern Med 170:1656–1663

    Article  PubMed  Google Scholar 

  32. Pistor K (1995) Akutes Nierenversagen. Monatsschr Kinderheilkd 143:1039–1040

    Google Scholar 

  33. Reddy PS, Deauna-Limoya D, Cook J, Ganguly SS et al (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84:232–235

    Article  PubMed  CAS  Google Scholar 

  34. Reinhart K, Brunkhorst FM, Bone HG et al (2010) Prävention, Diagnose, Therapie und Nachsorge der Sepsis. Erste Revision der S2 k-Leitlinien der Deutschen Sepsis-Gesellschaft e. V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI). Intensivmedizin 47:185–207

    Article  Google Scholar 

  35. Richardson PG, Murakami C, Jin Z et al (2002) Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100:4337–4343

    Article  PubMed  CAS  Google Scholar 

  36. Sibai BM, Ramadan MK, Usta I et al (1993) Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 169:1000–1006

    PubMed  CAS  Google Scholar 

  37. Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073–1086

    PubMed  CAS  Google Scholar 

  38. Taylor FB Jr, Toh CH, Hoots WK et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intracascular coagulation. Thromb Haemost 86:1327–1330

    PubMed  CAS  Google Scholar 

  39. Taylor CM, Machin S, Wigmore SJ, Goodship THJ (2009) Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kongdom. Br J Haematol 148:37–47

    Article  PubMed  Google Scholar 

  40. Wadleigh M, Ho V, Momtaz P, Richardson P (2003) Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 10:451–462

    Article  PubMed  Google Scholar 

  41. Warkentin TE (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535–555

    Article  PubMed  CAS  Google Scholar 

  42. Warren BL, Eid A, SingerP, Pillay SS et al (2001) High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 286:1869–1878

    Article  PubMed  CAS  Google Scholar 

  43. Zimmerhackl LB, Besbas N, Jungraithmayr T, Kar N van de et al (2006) Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 32:113–120

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Krankenhaus Köthen GmbH, Hallesche Str. 29, 06366, Köthen, Deutschland

    L. Engelmann

Authors
  1. L. Engelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Engelmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Engelmann, L. Thrombophile Zustände in der Intensivmedizin. Med Klin 106, 189–197 (2011). https://doi.org/10.1007/s00063-011-0015-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-011-0015-8

Schlüsselwörter

Keywords

Search

Navigation